# Viracta Therapeutics Inc. (VIRX)

Source: https://www.quantisnow.com/company/VIRX
Generated: 2026-11-16T01:08:58.789Z

- Ticker: VIRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2005
- Website: viracta.com

## About

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.

## Latest VIRX news and filings

- 2025-02-05 22:00 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-5873610)
- 2025-02-05 22:00 UTC [Leadership Update] [Viracta Therapeutics Announces Wind Down of Operations](https://www.quantisnow.com/insight/viracta-therapeutics-announces-wind-down-of-operations-5873586)
- 2025-01-31 21:30 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5865421)
- 2025-01-24 22:14 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-entry-into-a-5856983)
- 2025-01-17 21:08 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5849866)
- 2024-12-26 21:39 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-events-that-accelerate-5825269)
- 2024-12-26 21:30 UTC [Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives](https://www.quantisnow.com/insight/viracta-therapeutics-announces-closure-of-naval-1-clinical-trial-and-exploration-5825199)
- 2024-11-29 22:14 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5794828)
- 2024-11-27 21:08 UTC [SEC Form 4] [Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 839,741 units (SEC Form 4)](https://www.quantisnow.com/insight/director-royston-ivor-converted-options-into-25219-shares-increasing-direct-5793472)
- 2024-11-27 21:06 UTC [SEC Form 4] [Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 126,478 units (SEC Form 4)](https://www.quantisnow.com/insight/director-pomerantz-roger-converted-options-into-9034-shares-increasing-direct-5793458)
- 2024-11-22 22:20 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5788918)
- 2024-11-14 21:33 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Viracta Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-viracta-therapeutics-inc-5776471)
- 2024-11-13 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Viracta Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-viracta-therapeutics-inc-5771842)
- 2024-11-13 12:30 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-results-of-operations-5769924)
- 2024-11-13 12:00 UTC [Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/viracta-therapeutics-reports-third-quarter-2024-financial-results-and-provides-5769781)
- 2024-11-06 21:46 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-costs-associated-with-5756392)
- 2024-11-06 21:30 UTC [Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma](https://www.quantisnow.com/insight/viracta-therapeutics-announces-reprioritization-of-resources-to-enhance-focus-on-5756139)
- 2024-09-12 22:13 UTC [SEC Form 4] [Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 814,522 units (SEC Form 4)](https://www.quantisnow.com/insight/director-royston-ivor-converted-options-into-25219-shares-increasing-direct-5692606)
- 2024-09-12 22:10 UTC [SEC Form 4] [Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 117,444 units (SEC Form 4)](https://www.quantisnow.com/insight/director-pomerantz-roger-converted-options-into-9034-shares-increasing-direct-5692604)
- 2024-09-03 11:00 UTC [Conference Announcement] [Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference](https://www.quantisnow.com/insight/viracta-therapeutics-to-present-at-the-hc-wainwright-26th-annual-5678829)
- 2024-08-16 11:39 UTC [Analyst Downgrade] [Viracta Therapeutics downgraded by Leerink Partners with a new price target](https://www.quantisnow.com/insight/viracta-therapeutics-downgraded-by-leerink-partners-with-a-new-price-5662263)
- 2024-08-14 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Viracta Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-viracta-therapeutics-inc-5659036)
- 2024-08-14 11:15 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-results-of-operations-5658144)
- 2024-08-14 11:05 UTC [Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/viracta-therapeutics-reports-second-quarter-2024-financial-results-and-provides-5658119)
- 2024-08-14 11:00 UTC [Earnings Date] [Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan](https://www.quantisnow.com/insight/viracta-therapeutics-announces-positive-data-from-the-phase-2-naval-1-5658047)
- 2024-07-26 22:38 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-costs-associated-with-5630431)
- 2024-06-24 23:50 UTC [SEC Form 4] [SEC Form 4 filed by Director Royston Ivor](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-royston-ivor-5574625)
- 2024-06-24 23:49 UTC [SEC Form 4] [SEC Form 4 filed by Director Borellini Flavia](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-borellini-flavia-5574620)
- 2024-06-24 23:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Chung Jane](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-chung-jane-5574616)
- 2024-06-24 23:47 UTC [SEC Form 4] [SEC Form 4 filed by Director Murphy Samuel Lafayette](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-murphy-samuel-lafayette-5574614)
- 2024-06-24 23:46 UTC [SEC Form 4] [SEC Form 4 filed by Director Darcy Thomas E](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-darcy-thomas-e-5574611)
- 2024-06-24 23:44 UTC [SEC Form 4] [SEC Form 4 filed by Director Simon Barry J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-simon-barry-j-5574609)
- 2024-06-24 23:43 UTC [SEC Form 4] [SEC Form 4 filed by Director Barlow Jane F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-barlow-jane-f-5574606)
- 2024-06-24 23:40 UTC [SEC Form 4] [SEC Form 4 filed by Director Pomerantz Roger](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-pomerantz-roger-5574604)
- 2024-06-24 23:39 UTC [SEC Form 4] [SEC Form 4 filed by Director Rubino Stephen](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rubino-stephen-5574600)
- 2024-06-20 20:08 UTC [SEC Form 8-K] [SEC Form 8-K filed by Viracta Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-viracta-therapeutics-inc-5568589)
- 2024-06-18 19:05 UTC [Market Chatter] [VIRX Granted US Patent #12012396 For "HDAC Inhibitor Solid State Forms (For The Treatment Of Cancer, Immune Disorders)"](https://www.quantisnow.com/insight/virx-granted-us-patent-12012396-for-hdac-inhibitor-solid-state-5564808)
- 2024-06-11 12:06 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-pre-market-session-5550052)
- 2024-05-31 20:46 UTC [SEC Form 8-K] [Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/viracta-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5530005)
- 2024-05-29 23:12 UTC [SEC Form 4] [Pomerantz Roger converted options into 9,035 shares, increasing direct ownership by 9% to 108,410 units (SEC Form 4)](https://www.quantisnow.com/insight/pomerantz-roger-converted-options-into-9035-shares-increasing-direct-ownership-5524107)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VIRX
- Earnings history: https://www.quantisnow.com/earnings/VIRX
- Dividend history: https://www.quantisnow.com/dividends/VIRX
- Insider transactions: https://www.quantisnow.com/insiders/VIRX
- Options chain: https://www.quantisnow.com/options/VIRX
- SEC 8-K filings only: https://www.quantisnow.com/company/VIRX/8-k
- RSS and alerts for VIRX: https://www.quantisnow.com/docs/rss-feeds.md
